Emicizumab for the prevention of bleeds in hemophilia A
暂无分享,去创建一个
[1] J. Oldenburg,et al. The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[2] Anisha M. Patel,et al. Management of Persons with Hemophilia A with Inhibitors After Emicizumab Approval , 2018, Blood.
[3] Zheng-Yi Zhou,et al. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A , 2018, Journal of managed care & specialty pharmacy.
[4] Tomoko Matsumoto,et al. A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab , 2018, Blood.
[5] J. Antovic,et al. Combined Effect of By-Pass Agents and a Sequence Identical Analogue of Emicizumab on Fibrin Clot Turbidity and Structure in Factor VIII Deficient Plasma , 2018, Blood.
[6] P. Kuebler,et al. Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies , 2018, Blood.
[7] A. Ishiguro,et al. Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study) , 2018, Blood.
[8] W. Sperr,et al. Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases , 2018, Blood.
[9] K. Nogami,et al. Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model , 2018, Blood.
[10] S. Meeks,et al. The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab , 2018, Blood.
[11] A. Schmaier,et al. A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia , 2018, Blood.
[12] S. Corman,et al. Model of the Impact of Delayed Inhibitor Development on Cumulative Breakthrough Bleeds and Costs in Persons with Hemophilia A Receiving Emicizumab Prophylaxis , 2018, Blood.
[13] J. Oldenburg,et al. Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study , 2018, Blood.
[14] S. Meeks,et al. Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis , 2018, Blood.
[15] D. Kudrow,et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine , 2018, BMC Neurology.
[16] G. Young. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. , 2018, Blood advances.
[17] C. Négrier,et al. Emicizumab should be prescribed independent of immune tolerance induction. , 2018, Blood advances.
[18] S. Pipe,et al. Emicizumab for hemophilia A with factor VIII inhibitors , 2018, Expert review of hematology.
[19] W. Gerner,et al. Safety and immune responses after intradermal application of Porcilis PRRS in either the neck or the perianal region , 2018, PloS one.
[20] J. Oldenburg,et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors , 2018, The New England journal of medicine.
[21] K. Nogami,et al. Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V , 2018, British journal of haematology.
[22] L. Valentino,et al. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents , 2018, Journal of thrombosis and haemostasis : JTH.
[23] K. Nogami,et al. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti‐idiotype monoclonal antibodies , 2018, Journal of thrombosis and haemostasis : JTH.
[24] Tomoko Matsumoto,et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab , 2018, Journal of thrombosis and haemostasis : JTH.
[25] P. Mannucci. Miracle of haemophilia drugs: Personal views about a few main players , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[26] M. Makris,et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[27] J. Mahlangu,et al. Emerging therapies for haemophilia ‐ Global perspective , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.
[28] K. Nogami,et al. The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity. , 2018, Thrombosis research.
[29] J. Oldenburg,et al. Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2) , 2017 .
[30] J. Oldenburg,et al. HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors , 2017 .
[31] O. Christophe,et al. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? , 2017, Blood.
[32] J. Oldenburg,et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.
[33] A. Akinc,et al. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy , 2017, The New England journal of medicine.
[34] J. Oldenburg,et al. Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.
[35] A. Chuansumrit,et al. Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage – the MUSFIH study , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.
[36] K. Nogami,et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens , 2017, Thrombosis and Haemostasis.
[37] Sunil V. Rao,et al. Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect. , 2017, Journal of the American College of Cardiology.
[38] K. Wyrwich,et al. Changes in health‐related quality of life with treatment of longer‐acting clotting factors: results in the A‐LONG and B‐LONG clinical studies , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[39] E. Rodríguez‐Merchán. Musculo-skeletal manifestations of haemophilia. , 2016, Blood reviews.
[40] J. Mahlangu,et al. TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[41] E. Santagostino,et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. , 2016, Blood.
[42] J. Oldenburg,et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A , 2016, Thrombosis and Haemostasis.
[43] J. Mahlangu,et al. Extended half‐life clotting factor concentrates: results from published clinical trials , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[44] L. Valentino,et al. Orthopedic disorders of the knee in hemophilia: A current concept review. , 2016, World journal of orthopedics.
[45] Tetsuji Sato,et al. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. , 2016, The New England journal of medicine.
[46] E. Berntorp,et al. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products , 2016, Seminars in Thrombosis & Hemostasis.
[47] K. Yoneyama,et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. , 2016, Blood.
[48] P. Monahan. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors. , 2015, Hematology. American Society of Hematology. Education Program.
[49] E. Santagostino,et al. Optimising musculoskeletal care for patients with haemophilia , 2015, European journal of haematology.
[50] C. Witmer. Low mortality from intracranial haemorrhage in paediatric patients with haemophilia , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.
[51] S. Lethagen,et al. Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial , 2015, Journal of thrombosis and haemostasis : JTH.
[52] J. Astermark,et al. Genetic risk factors for inhibitors in haemophilia A , 2015, European journal of haematology.
[53] T. Igawa,et al. Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity , 2014, mAbs.
[54] Won Chan Lee,et al. Impact of haemophilia with inhibitors on caregiver burden in the United States , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[55] M. Carcao. Changing paradigm of prophylaxis with longer acting factor concentrates , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[56] J. Dumont,et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.
[57] R. Kaufman,et al. Molecular approaches for improved clotting factors for hemophilia. , 2013, Hematology. American Society of Hematology. Education Program.
[58] A. I. Vorobiev,et al. Blood Clotting Factor VIII: From Evolution to Therapy , 2013, Acta naturae.
[59] J. Mahlangu,et al. Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[60] T. Kennedy-Martin,et al. A systematic review of the cost‐effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.
[61] F. Rosendaal,et al. Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study 1 , 2006, Journal of thrombosis and haemostasis : JTH.
[62] K. Fischer,et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[63] F. Rosendaal,et al. Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.
[64] F. Dorner,et al. Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime. , 1999, Wiener klinische Wochenschrift.
[65] W. G. Aken,et al. Availability of clotting factor concentrates in genetically engineered form. , 1998 .
[66] A. J. Stewart,et al. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[67] W. van Aken. Availability of clotting factor concentrates in genetically engineered form. , 1998, Transfusion science.
[68] P. Mannucci,et al. The choice of plasma-derived clotting factor concentrates. , 1996, Bailliere's clinical haematology.
[69] E. Beutner,et al. Report of a WHO Scientific Group (Part 3 of 3) , 1973 .